Amgen traded at $245.55 this Friday July 1st, increasing $2.25 or 0.92 percent since the previous trading session. Looking back, over the last four weeks, Amgen gained 1.10 percent. Over the last 12 months, its price fell by 1.27 percent. Looking ahead, we forecast Amgen to be priced at 238.77 by the end of this quarter and at 220.01 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
245.55
Daily Change
0.92%
Yearly
-1.27%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Takeda 3,759.00 -59.00 -1.55% 0.16%
AbbVie 153.80 0.64 0.42% 33.54%
Agios Pharmaceuticals 23.36 1.19 5.37% -58.08%
ALKERMES 30.53 0.74 2.48% 20.67%
Amgen 245.55 2.25 0.92% -1.27%
Astrazeneca 65.95 -0.12 -0.18% 8.49%
Biogen 210.63 6.69 3.28% -39.60%
Bluebird Bio 4.28 0.14 3.38% -86.36%
BioMarin Pharmaceutical 84.98 2.11 2.55% -0.57%
Bristol-Myers Squibb 76.84 -0.16 -0.21% 14.77%
Coherus Biosciences 7.83 0.59 8.15% -42.97%
Exelixis 21.57 0.75 3.60% 18.13%
Genmab 2,361.00 64.00 2.79% -9.30%
Gilead Sciences 62.36 0.55 0.89% -10.01%
GlaxoSmithKline 1,785.60 20.00 1.13% 24.19%
Glaxosmithkline 43.75 0.22 0.51% 8.27%
Intercept Pharmaceuticals 14.13 0.32 2.32% -29.31%
Incyte Corp 77.67 1.70 2.24% -7.07%
Ionis Pharmaceuticals 38.06 1.04 2.81% -4.66%
J&J 179.52 2.01 1.13% 6.24%
Eli Lilly 324.71 0.48 0.15% 38.79%
Merck & Co 92.42 1.25 1.37% 17.58%
Moderna Inc 149.95 7.10 4.97% -36.00%
Mirati Therapeutics 71.18 4.05 6.03% -57.53%
Neurocrine Biosciences 99.25 1.77 1.82% 0.65%
Novartis 80.33 -0.52 -0.64% -4.96%
Novartis 84.36 -0.17 -0.20% -8.28%
Puma Biotechnology 2.78 -0.07 -2.46% -68.48%
Pfizer 52.31 -0.12 -0.23% 31.66%
PTC Therapeutics 41.85 1.79 4.47% -2.88%
Ultragenyx Pharmaceutical 62.65 2.99 5.01% -33.50%
Regeneron Pharmaceuticals 595.40 4.27 0.72% 2.01%
Roche Holding 320.40 1.85 0.58% -8.34%
Sanofi 97.52 1.18 1.22% 10.94%
Seattle Genetics 180.11 3.17 1.79% 14.52%
Sarepta Therapeutics 75.71 0.75 1.00% 0.62%
Teva Pharmaceutical Industries Ltd 2,670.00 -83.00 -3.01% -18.10%
Vertex Pharmaceuticals 287.32 5.53 1.96% 43.27%

Indexes Price Day Year
US500 3825 39.95 1.06% -12.11%
USND 11128 99.11 0.90% -23.99%
USNDX 11586 81.96 0.71% -21.33%
US30 31097 321.83 1.05% -10.61%

Amgen
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq). It focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.